Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

Part of paid clinical trials in Glendale, California.

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT07594093
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Overweight or Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • REGN20934 — DRUG
    Administered per the protocol
  • Placebo — DRUG
    Administered per the protocol

Study Details

This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934

Key Dates

Start date
Jun 29, 2026
Status verified
Jul 2026
Primary completion
Feb 22, 2027
Completion
Feb 22, 2027

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: REGN20934
  • Placebo Comparator: Placebo

Primary Outcome Measure

Occurrence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 16 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
California Clinical Trials Medical GroupGlendaleCalifornia91206-

Find similar trials in Glendale, CA

By research site
California Clinical Trials Medical Group· Glendale, CA

Related Studies